Pacira BioSciences, Inc. (NASDAQ:PCRX) Position Boosted by EntryPoint Capital LLC

EntryPoint Capital LLC increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 44.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,021 shares of the company’s stock after purchasing an additional 7,062 shares during the period. EntryPoint Capital LLC’s holdings in Pacira BioSciences were worth $434,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its position in shares of Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after acquiring an additional 513 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after purchasing an additional 918 shares during the period. Caitlin John LLC increased its stake in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Pacira BioSciences by 17.4% during the fourth quarter. Teacher Retirement System of Texas now owns 13,708 shares of the company’s stock worth $258,000 after purchasing an additional 2,034 shares during the period. Finally, Global Alpha Capital Management Ltd. lifted its position in shares of Pacira BioSciences by 5.7% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 39,900 shares of the company’s stock worth $752,000 after buying an additional 2,160 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Stock Performance

PCRX stock opened at $24.54 on Wednesday. The company has a 50-day simple moving average of $24.60 and a 200 day simple moving average of $19.76. The company has a market capitalization of $1.14 billion, a P/E ratio of -12.09 and a beta of 0.86. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PCRX. HC Wainwright boosted their price objective on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC increased their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Finally, Barclays boosted their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $27.22.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.